nach oben

International Journal of Clinical Oncology

Erschienen in:

01.06.2010 | Review Article

Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science

verfasst von: Shinji Tanaka, Shigeki Arii

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Conventional systemic chemotherapy has been developed with so-called anti-cancer agents, essentially screened for cytotoxicity to cultured cancer cells. However, in patients with hepatocellular carcinoma (HCC), the role of chemotherapy is quite limited because most anti-cancer agents are ineffective and relatively toxic to HCC patients with chronic liver diseases. On the other hand, accumulated understanding of the molecular mechanisms regulating cancer progression has led to novel development of molecularly targeted therapies with cytostatic agents. Recently, a phase III clinical trial revealed a multi-kinase inhibitor, Sorafenib, as the first agent leading to improved overall survival of patients with advanced HCC. A new era of HCC treatment has arrived, based on identification of deranged signaling pathways of cancer cells or their microenvironment. This review summarizes the molecular hallmarks of HCC with a focus on angiogenesis, growth signals, and mitotic stress, and a novel concept “synthetic lethality” for the targeted therapy strategy.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70CrossRefPubMed

Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13(6):472–482CrossRefPubMed

Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136(5):823–837CrossRefPubMed

Weinstein IB (2002) Cancer. addiction to oncogenes-the Achilles heal of cancer. Science 297(5578):63–64CrossRefPubMed

Weinstein IB, Joe AK (2006) Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3(8):448–457CrossRefPubMed

Tanaka S, Arii S (2009) Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 100(1):1–8CrossRefPubMed

Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312–1327CrossRefPubMed

Yau T, Chan P, Epstein R et al (2009) Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 29(1):10–17 ReviewCrossRefPubMed

Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364CrossRefPubMed

10.

Tanaka S, Arii S (2006) Current status of perspective of antiangiogenic therapy for cancer; hepatocellular carcinoma. Int J Clin Oncol 11:82–89CrossRefPubMed

11.

Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10):795–803CrossRefPubMed

12.

Mise M, Arii S, Higashituji H et al (1996) Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23(3):455–464CrossRefPubMed

13.

Schmitt M, Horbach A, Kubitz R et al (2004) Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol 41(2):274–283CrossRefPubMed

14.

Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820–827CrossRefPubMed

15.

Hiratsuka S, Watanabe A, Aburatani H et al (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8(12):1369–1375CrossRefPubMed

16.

Arii S (2004) Role of vascular endothelial growth factor on the invasive potential of hepatocellular carcinoma. J Hepatol 41(2):333–335CrossRefPubMed

17.

Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276–1312CrossRefPubMed

18.

Kuhnert F, Tam BY, Sennino B et al (2008) Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci USA 105(29):10185–10190CrossRefPubMed

19.

Uematsu S, Higashi T, Nouso K et al (2005) Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 20(4):583–588CrossRefPubMed

20.

Poon RT, Ng IO, Lau C et al (2001) Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182:298–304CrossRefPubMed

21.

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed

22.

Tanaka S, Mori M, Sakamoto Y et al (1999) Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Investig 103(3):341–345CrossRefPubMed

23.

Tanaka S, Wands JR, Arii S (2006) Induction of angiopoietin-2 gene expression by COX-2: A novel role for COX-2 inhibitors during hepatocarcinogenesis. J Hepatol 44(1):233–235CrossRefPubMed

24.

Tanaka S, Sugimachi K, Yamashita Yi et al (2002) Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 35(4):861–867CrossRefPubMed

25.

Seegar TC, Eller B, Tzvetkova-Robev D et al (2010) Tie1–Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell 37(5):643–655CrossRefPubMed

26.

Holash J, Maisonpierre PC, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284(5422):1994–1998CrossRefPubMed

27.

Oliner J, Min H, Leal J et al (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6(5):507–516CrossRefPubMed

28.

Herbst RS, Hong D, Chap L et al (2009) Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27(21):3557–3565CrossRefPubMed

29.

Pawson T (2004) Specificity in signal transduction: from phosphotyrosine–SH2 domain interactions to complex cellular systems. Cell 116:191–203CrossRefPubMed

30.

Tanaka S, Sugimachi K, Maehara S et al (2002) Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinoma. Surgery 131:S142–S147CrossRefPubMed

31.

Schagdarsurengin U, Wilkens L, Steinemann D et al (2003) Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 22:1866–1871CrossRefPubMed

32.

Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687CrossRefPubMed

33.

Luo J, Manning BD, Cantley LC (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4:257–262CrossRefPubMed

34.

Chiang GG, Abraham RT (2007) Targeting the mTOR signaling network in cancer. Trends Mol Med 13:433–442CrossRefPubMed

35.

Foster KG, Fingar DC (2010) mTOR: conducting the cellular signaling symphony. J Biol Chem

36.

Schvartzman JM, Sotillo R, Benezra R (2010) Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 10(2):102–115CrossRefPubMed

37.

Tanaka S, Arii S, Yasen M et al (2008) Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 95:611–619CrossRefPubMed

38.

Keen N, Taylor S (2004) Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4:927–936CrossRefPubMed

39.

Nguyen HG, Makitalo M, Yang D et al (2009) Deregulated Aurora-B induced tetraploidy promotes tumorigenesis. FASEB J 23(8):2741–2748CrossRefPubMed

40.

Harrington EA, Bebbington D, Moore J et al (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10(3):262–267CrossRefPubMed

41.

Aihara A, Tanaka S, Yasen M et al (2010) The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 52(1):63–71CrossRefPubMed

42.

Tanaka S, Mogushi K, Yasen M et al (2010) Gene-expression phenotypes for vascular invasiveness of hepatocellular carcinomas. Surgery 147(3):405–414CrossRefPubMed

43.

Luo J, Emanuele MJ, Li D et al (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137(5):835–848CrossRefPubMed

44.

Dobzhansky T (1946) Genetics of natural populations. XIII. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 31:269–290PubMed

45.

Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5(9):689–698CrossRefPubMed

46.

Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134CrossRefPubMed

47.

Iglehart JD, Silver DP (2009) Synthetic lethality—a new direction in cancer-drug development. N Engl J Med 361(2):189–191CrossRefPubMed

48.

Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913–917CrossRefPubMed

49.

Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921CrossRefPubMed

50.

Ince N, Wands JR (1999) The increasing incidence of hepatocellular carcinoma. N Engl J Med 340:798–799CrossRefPubMed

51.

Arii S, Yamaoka Y, Futagawa S et al (2000) Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32:1224–1229CrossRefPubMed

52.

Tanaka S, Arii S (2010) Medical treatments: in association or alone, their role and their future perspectives: novel molecular-targeted therapy for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg

Titel: Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science
verfasst von: Shinji Tanaka
Shigeki Arii
Publikationsdatum: 01.06.2010
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 3/2010
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-010-0083-4

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Quality of guideline development assessed by the Evaluation Committee of the Japan Society of Clinical Oncology

A pretreatment nomogram predicting recurrence- and progression-free survival for nonmuscle invasive bladder cancer in Japanese patients

A case of rapidly growing pulmonary carcinosarcoma

Head and neck sarcoma: report of a case treated by intensity-modulated radiation therapy

Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice

Complete response of anaplastic pancreatic carcinoma to paclitaxel treatment selected by chemosensitivity testing

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie